ArticleBMC microbiology2026
Gut microbiota composition and functionality are associated with prolactin-secreting pituitary adenoma and serum lipid levels.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe changes in gut microbiota composition and their correlations with serum lipid levels in prolactin-secreting pituitary adenoma (PPA) patients remain unknown. This study investigates these alterations and associations and explores microbial markers for PPA diagnosis.
methodsA total of 101 participants were enrolled, comprising 72 PA patients (31 with prolactin-secreting adenomas and 41 with non-functioning adenomas, i.e., PPA and NFPA groups) and 29 age and sex-matched healthy controls (HC). Utilizing 16 S rRNA gene amplicon sequencing, we examined the gut microbiota community in the PPA group and investigated its associations with serum lipid levels.
resultsOur results revealed significantly reduced microbial ecosystem richness and evenness in PPA patients compared to healthy controls. The PA group, especially PPA, exhibited substantial alterations in gut microbiota structure, including increased abundance of gram-negative pathogenic bacteria such as Desulfovibrio and Enterobacter, and decreased levels of probiotic bacteria like Bifidobacterium. We also identified significant positive correlations between PPA-enriched bacteria and serum lipid levels. A biomarker panel (including Bifidobacterium, Dorea, Blautia, Morganella, Desulfovibrio, and Enterobacter) demonstrated good performance in differentiating between PA patients and healthy controls (AUC: 0.843). Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis unveiled dysregulations in fundamental physiological pathways, particularly lipid metabolism, within the PPA group.
conclusionsOur findings suggest that PA patients, particularly those with PPA, exhibit distinct host-microbe interactions compared to healthy controls. Notably, the intestinal flora, particularly in the PPA microenvironment, may play a role in contributing to tumor development by impacting fundamental metabolism, especially lipid metabolism. IMPORTANCE: Our study revealed that the gut microbiome is tightly linked to PPA, and the disturbed microbiome may regulate the risk of PPA in lipid metabolism. These findings, including the development of a biomarker panel, suggest the potential of intestinal flora as a diagnostic and predictive tool, emphasizing its significance as a preventive target for PPA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.